(NewsDirect)
By Meg Flippin, Benzinga
What HerbalifeLtd. (NYSE: HLF) did with supplements, StemtechCorporation. (OTCQB: STEK) is setting out to do with stem cellnutrition, a growing market, with the global stem cells market set toreach almost$30 billion by 2030 growing at a CAGR of 14.9% over 2023-2030.
The Naples, Florida company develops products to support wellness using the body’s stem cells.Stemtech says its stem cell enhancers improve the body’s naturaldefense, renewal, rejuvenation and anti-aging processes. Studies showthe more stem cells you have circulating in your blood, the greaterthe ability of your body to renew itself naturally. Stemtech’sproducts also boast powerful anti-aging components that are attractingconsumers and independent sellers alike.
That puts it on a similar path as Herbalifewhich came on the scene in the 1980s and built itself into apowerhouse, with revenue of morethan $5 billion in 2022 and a market cap of about $1.3billion as of December 5. Herbalife was able to capitalize onthe increased focus on wellness, delivering products that metconsumers' needs. Stemtech is doing the same with its stem-cellenhancers, which promise to boost health and slow aging.
ScienceTo Back It Up
Stemtech isn’t the only company going after this market, butits science-based nutrition may give it an edge. Stemrelease3™,StemFlo Advanced® and MigraStem™ are comprised of superfoodextracts, antioxidants, polysaccharides, vitamins, minerals and othernatural compounds. They are designed to support the healthy activityof our own stem cells and boost immune and circulatory systemfunctions. The nutrients in these three products also help to activatethe energy processes in the mitochondria, have antioxidant anddetoxification effects and support telomere health, according toStemtech. Healthy telomeres are a potent defense to the agingprocess.
Stemrelease3 TM ,Stemtech’s most advanced stem cell nutrition product, containsstemrelease3, a blend of clinically tested ingredients that Stemtechsays help release millions of your body’s stem cells from the bonemarrow into the bloodstream. Stemrelease also helps support telomerehealth. Stemtech’s unique work has granted them ownership over anumber of American andInternational patents .
Stemtech’s CellectOne™ Rapid Release Stem Cell Peptide Night Cream is anotherpopular product. It uses QXP, a patented, FDA-approved ingredient fromRed Oak Bark to regulate the body and lower the skin's barriers sostem cells and peptides containing antioxidants, peptides and proteincan be delivered to the skin, assisting in rejuvenating it. Stemtechsays its line of supplements and treatments is answering a need amongconsumers for anti-aging and wellness products that actually work.
Stemtech’s OraStem™ all-naturaltoothpaste helps support good oral care by whitening teeth, fresheningbreath, stem cell support, anti-microbial properties and supports goodgum health – all important for overallwellness.
Direct-To-Consumers
To get its stem cell-based supplements in the handsof consumers, Stemtech is taking a page from Herbalife, marketing toconsumers through a direct network of sellers. What Stemtech saysmakes it different is its business Academies. The program is designedto support the individuals selling Stemtech’s products. Through theBusiness Academies entrepreneurs get access to resources includingmentorship and industry insights. The idea is to help theentrepreneurs grow their businesses instead of just having them pushproducts. Stemtech credits double-digitincreases in sales to this business approach. "Stemtech iswitnessing the increase in our Independent Business Partners network.This positive momentum is a testament to the appeal of Stemtech'sexceptional anti-aging products and the promising income-earningopportunity we offer," Stemtech President and COO John W. Meyersaid ina recent press release .
Justas Herbalife was on the cutting edge when it launched its lines ofvitamins, shakes and beauty supplements in 1980, Stemtech ispositioning itself as a first mover in what is forecast to be agrowing global market. Demand for wellness and anti-aging vitamins andsupplements is forecast to surge in the years to come. As will demandfor stem-cell products. The global health and wellness market isexpected to be worth $13.89trillion by 2032, growing at a CAGR of 10.93% over2023-2032.
The Next Herbalife?
Despite all this, shares of Stemtech aretrading near lows. Herbalife’s stock has weathered various storms,indicative of its resilience, and Stemtech plans to follow the samebusiness path. Investors looking for companies in their nascent stagesmay want to look into this innovator focused on the cutting-edge stemcell nutrition segment. Stemtech seems well-positioned to takeadvantage of a projected boom in the stem cell sector, and the companyis confident of its future outlook.
Herbalife showed the world how to live healthilythrough supplements and shakes. Stemtech is betting it can turn backthe clock, rejuvenate the body and extend life with its stem cellproducts.
Stemtech Corporation, a leading stemceutical™company with a direct sales distribution model, was founded on April18, 2018, after acquiring the operations from its predecessor StemtechInternational, Inc., which was established in 2005. From 2010 through2015, Stemtech International, Inc., was recognized four separate timeson the Inc. 5000 Fastest-Growing Companies list. In 2018, Stemtechunderwent an extensive executive reorganization, and continuedoperations under new leadership as Stemtech Corporation. In August2021, Stemtech became a publicly traded company (OTCQB:STEK) and hasexpanded business opportunities for its Independent Business Partners,who may earn incomes by sharing Stemtech products. January 2022 sawthe introduction of new marketing efforts. In September 2022, the newStemtech AdvanceOffice mobile app based on the VERB Technologyplatform was successfully launched as a powerful communication -recruiting tool for our Field On November 1, 2022, Stemtech introducedthe new travel/sample size OraStem® Toothpaste. On December 6,Stemtech announced the promotion of Alejandro Carrillo to the role ofVice President Global Sales from his current role as Managing DirectorLatin Markets. Stemtech introduced the new CellectOne™ Rapid RenewStem Cell Peptide Night Cream at their December 2022 InternationalLeadership Event in Cancun, Mexico. January 10, 2023. Stemtechappoints Margie and Mike Mares to Field Advisory Board. Stemtech hasRanked Number 11 in Momentum out of 700+ top Global MLM companies byBusiness For Home independent MLM publication, January 23, 2023.Stemtech conducted Field Leadership Business Academies in AguasCalientes, Mexico May 25 - 27, and in Las Vegas, NV on June 1 - 3.Stemtech rewards top Field Leaders with reward cruise in the SouthCaribbean December 9 - 16 2023 aboard the Royal Caribbean Rhapsody ofthe Seas.
This announcement contains forward-lookingstatements within the meaning of the “safe harbor” provisions ofthe U.S. Private Securities Litigation Reform Act of 1995. Suchstatements include but are not limited to statements identified bywords such as "believes," "expects,""anticipates," "estimates," "intends,""plans," "targets," "projects" and similarexpressions. The statements in this release are based upon the currentbeliefs and expectations of our company's management and aresubject to significant risks and uncertainties. Actual results maydiffer from those set forth in the forward-looking statements.Numerous factors could cause or contribute to such differences,including, but not limited to, results of clinical trials and/or otherstudies, the challenges inherent in new product developmentinitiatives, the effect of any competitive products, our ability tolicense and protect our intellectual property, our ability to raiseadditional capital in the future that is necessary to maintain ourbusiness, changes in government policy and/or regulation, potentiallitigation by or against us, any governmental review of our productsor practices, as well as other risks discussed from time to time inour filings with the Securities and Exchange Commission, including,without limitation, our latest 10-Q Report filed on December 1, 2023.We undertake no duty to update any forward-looking statement, or anyinformation contained in this press release or in other publicdisclosures at any time. Finally, the investing public is remindedthat the only announcements or information about Stemtech Corporationwhich are condoned by the Company must emanate from the Company itselfand bear our name as its Source.
This post containssponsored content. This content is for informational purposes only andnot intended to be investing advice.
ContactDetails
Gabriel Rodriguez
CompanyWebsite
Copyright (c) 2023 TheNewswire - All rights reserved.